Premium
Long‐term culture and characterization of human neurofibroma‐derived Schwann cells
Author(s) -
Rosenbaum Thorsten,
Rosenbaum Claudia,
Winner Ursula,
Müller Hans Werner,
Lenard HansGerd,
Hanemann C. Oliver
Publication year - 2000
Publication title -
journal of neuroscience research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.72
H-Index - 160
eISSN - 1097-4547
pISSN - 0360-4012
DOI - 10.1002/1097-4547(20000901)61:5<524::aid-jnr7>3.0.co;2-z
Subject(s) - neurofibroma , schwann cell , neurofibromatosis , plexiform neurofibroma , biology , phenotype , cell culture , microbiology and biotechnology , carcinogenesis , pathology , cancer research , medicine , genetics , cancer , gene
Neurofibromas are benign tumors arising from the peripheral nerve sheath and are a typical finding in neurofibromatosis type 1 (NF1). Schwann cells are the predominant cell type in neurofibromas and thus are supposed to play a major role in the pathogenesis of these tumors. It is not known, however, if NF1 mutations in Schwann cells result in an altered phenotype that subsequently leads to tumor formation. To characterize the biological properties of neurofibroma‐derived Schwann cells we developed cell culture techniques that enabled us to isolate Schwann cells from neurofibromas and grow them in vitro for several weeks without significant fibroblast contamination. Neurofibroma‐derived Schwann cells were characterized by altered morphology, heterogeneous growth behavior, and increased expression of the P0 antigen while several other features of normal human Schwann cells were retained. We conclude that neurofibroma‐derived Schwann cells exhibit a distinct phenotype in vitro but that the observed abnormalities by themselves are insufficient to explain neurofibroma formation. Application of our improved culture conditions makes neurofibroma‐derived Schwann cells readily available for further studies to define their role in tumorigenesis in neurofibromatosis type 1. J. Neurosci. Res. 61:524–532, 2000. © 2000 Wiley‐Liss, Inc.